Ultrasensitive diagnostics using RNA fragmentomics
| Reference number | |
| Coordinator | Göteborgs universitet - Göteborgs universitet Inst f biomedicin |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | October 2024 - October 2025 |
| Status | Ongoing |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Purpose and goal
The project aims to develop RNA Fragmentomics, which is a new diagnostic concept to analyze blood-based biomarkers, and with AI-modelling optimize treatment of each patient. The solution has a decisive advantage over today´s multi-marker methods that require parallel workflows, which is practically complicated to implement. Blood samples can be taken routinely at outstations, giving patients’ access to specialist care in a smooth, decentralized and cost-effective way.
Expected effects and result
The project´s long-term objective is to introduce a new technology platform in Sweden for improved health, which leads to development and growth for Swedish and American companies, where Swedish research also gets early access to a coming analytical method. The project contributes to sustainable growth and development. Our pilot study is the first of its kind and the aim is to establish a complete workflow for sarcoma patients, who have a great need for improved treatments.
Planned approach and implementation
We are conducting an RNA fragmentomics study on blood samples from sarcoma patients to identify treatment-indicative biomarkers. RNA fragmentomics is a new technology that enables the analysis of more than 100,000 biomarkers. Project partners: RealSeq Biosciences, USA, who developed the experimental technology, MultiD Analyses who develops the methods to analyze the data and the software used, and Göteborg University/Sahlgrenska University Hospital, who is the end user.